Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis

Antimicrob Agents Chemother. 2004 Aug;48(8):3154-8. doi: 10.1128/AAC.48.8.3154-3158.2004.

Abstract

Using an inhalation model of pulmonary aspergillosis, we observed modest differences in the survival rates of mice treated with granulocyte colony-stimulating factor (G-CSF) and posaconazole (POS) and those treated with POS alone. This finding is in contrast to a previous report that suggested that G-CSF had a significant antagonistic effect on the antifungal activity of POS.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antifungal Agents / therapeutic use*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy*
  • Aspergillosis, Allergic Bronchopulmonary / microbiology
  • Aspergillosis, Allergic Bronchopulmonary / mortality
  • Drug Therapy, Combination
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Lung / microbiology
  • Male
  • Mice
  • Survival Analysis
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • Granulocyte Colony-Stimulating Factor
  • posaconazole